Company: LNAI
Filing Date: 2025-02-19
Form Type: 10-K/A
Source: 0001731122-25-000252
Chunk: 133

Company: Lunai Bioworks Inc.
Filing Date: 2025-02-19
Form: 10-K/A
Chunk 133
---
 |   |     |   |    11,640,000 |   |
| Total Indefinite Life Intangible Assets |     |          |             | $ |    73,211,000 |   |     | $ | (18,960,000   | ) |     | $ |                              — |   |     | $ |    54,251,000 |   |

F-16

Expected future amortization expense is as follows:

| Schedule of expected future amortization expense 
 Years                                            
 ended June 30,                                   |     |   |        |
|:-------------------------------------------------|:----|:--|-------:|
| 2025                                             |     | $ |  7,511 |
| 2026                                             |     |   |  7,511 |
| 2027                                             |     |   |  7,511 |
| 2028                                             |     |   |  7,510 |
| Total                                            |     | $ | 30,043 |

During February 2018, the Company
acquired IPR&D related to a License Agreement (as licensee) to an HIV therapy which consists of a perpetual, fully paid-up, royalty-free,
sub-licensable, and sole and exclusive worldwide license to research, develop, use, sell, have sold, make, have made, offer for sale,
import and otherwise commercialize certain intellectual property in cellular therapies for the prevention, treatment, amelioration of
and/or therapy exclusively for HIV in humans, and research and development exclusively relating to HIV in humans. The IPR&D intangible
asset was classified as an indefinite life asset that was tested annually for impairment.

On February 13, 2024, the Company
acquired Renovaro Cube as a wholly owned subsidiary pursuant to a stock purchase agreement. As part of the acquisition of Renovaro
Cube, the Company acquired goodwill valued at $159,464,039.

Impairment – On March 1, 2024, the Company received a notice from the sole manager of Weird Science LLC terminating the License Agreement by and between Weird Science LLC and Enochian Biopharma, Inc. (now known as Renovaro Biosciences, Inc.), a wholly owned subsidiary of the Company, dated February 16, 2018. Due to the termination of the License Agreement, the Company recorded an impairment of $42,611,000 during the year ended June 30, 2024.